Gilead announces interim Phase 2 data for idelalisib showing response in refractory indolent non-Hodgkin’s lymphoma
17 July 2013 | By Gilead Sciences
Results from Phase 2 study...
List view / Grid view
News
Boehringer Ingelheim and EFSD announce first recipients of diabetes research funding
17 July 2013 | By Boehringer Ingelheim
BI and EFSD commit €2.5 million to help accelerate European initiatives...
Novartis announces final agreement with Dr. Daniel Vasella
17 July 2013 | By Novartis
The Novartis Board of Directors announced a final agreement with its former Chairman, Dr. Daniel Vasella.
A 3D InSight™ into drug discovery with Tecan’s Infinite® M200 PRO
A novel solution for analyzing 3D cell cultures, based on Tecan’s Infinite® M200 PRO and InSphero’s 3D InSight™ microtissue technology, is helping to reduce the cost of early phase drug development.
The Lancet Oncology publishes results of XGEVA® (denosumab)
16 July 2013 | By Amgen
Phase 2 study reports safety and efficacy results in patients with giant cell tumor of bone...
GSK issue response to China investigation
16 July 2013 | By GSK
GSK issue a statement In response to the ongoing investigations by government authorities in China...
Approvals and launch update for XELJANZ® (tofacitinib citrate)
16 July 2013 | By Pfizer Inc.
Pfizer provides update on XELJANZ® (tofacitinib citrate) for the treatment of rheumatoid arthritis...
FDA approves Gilotrif™ (afatinib) as first-line treatment for lung cancer patients with EGFR mutations
16 July 2013 | By Boehringer Ingelheim
First approval for afatinib, the frontrunner from Boehringer Ingelheim’s new oncology pipeline...
Roche’s Erivedge receives conditional EU approval for treatment of advanced basal cell carcinoma
15 July 2013 | By Roche
The European Commission has granted conditional approval to Erivedge...
Simon Lowth, Chief Financial Officer, to leave AstraZeneca
15 July 2013 | By AstraZeneca
AstraZeneca announced that Simon Lowth, CFO and Executive Director, will leave the company at the end of October...
Merck presents findings from Phase 1b study of investigational BACE inhibitor, MK-8931, in patients with Alzheimer’s Disease
14 July 2013 | By Merck
Results from a Phase Ib study...
Daiichi Sankyo announces Phase 3 study results (PRASFIT-Elective study) for the antiplatelet agent prasugrel in Japan
12 July 2013 | By Daiichi Sankyo
Results of a phase 3 clinical study...
FDA accepts Eliquis® (apixaban) sNDA for review for prophylaxis of deep vein thrombosis following hip or knee replacement surgery
11 July 2013 | By Bristol-Myers Squibb Company
FDA accepted for review a sNDA for Eliquis®
Catalent and Biota Pharmaceuticals expand their alliance
10 July 2013 | By Catalent Pharma Solutions
Catalent Pharma Solutions has entered into a contract with Biota Pharmaceuticals, Inc...
Boehringer Ingelheim and Ashoka Changemakers announce winners of Transforming Health Systems competition
10 July 2013 | By Boehringer Ingelheim
“We were thrilled by the level of innovation...”
